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Deciphering the mechanisms of epigenetic reprogramming provides fundamental insights into cell fate de-
cisions, which in turn reveal strategies to make the reprogramming process increasingly efficient. Here we
review recent advances in epigenetic reprogramming to pluripotency with a focus on the principal molecular
regulators. We examine the trajectories connecting somatic and pluripotent cells, genetic and chemical
methodologies for inducing pluripotency, the role of endogenous master transcription factors in
establishing the pluripotent state, and functional interactions between reprogramming factors and epige-
netic regulators. Defining the crosstalk among the diverse molecular actors implicated in cellular reprogram-
ming presents a major challenge for future inquiry.Introduction
Since the initial discovery of induced pluripotent stem cells
(iPSCs) (Takahashi and Yamanaka, 2006), the process of
somatic cell reprogramming has been a source of fascination
for the scientific community and general public alike. Cellular re-
programming is inherently an epigenetic phenomenon. Heritable
modifications of DNA and chromatin, such as methylation of
cytosine residues and posttranslational modifications of his-
tones, regulate gene expression patterns during mammalian
development (Reik et al., 2001). Consequently, induced pluripo-
tency involves the dynamic rearrangement of epigenetic land-
scapes (Apostolou and Hochedlinger, 2013). The past several
years have seen concerted efforts to elucidate the mechanisms
of reprogramming, coalescing around several major questions:
What genes are required for successful reprogramming? Does
the process of epigenetic reprogramming follow a defined order
of molecular events? What are the major barriers to induced
pluripotency, and can these barriers be removed through genetic
or chemical intervention?
Here we present a conceptual framework for analyzing recent
mechanistic advances in epigenetic reprogramming to pluripo-
tency that distinguishes five categories of molecular actors: (1)
cell surface markers and pluripotency genes that serve as sign-
posts for discrete transitions during reprogramming; (2) tran-
scription factors, epigenetic regulators, and noncoding RNAs
that induce reprogramming; (3) small molecules and environ-
mental stimuli that replace the Yamanaka factors or induce novel
states of pluripotency; (4) endogenous master transcription fac-
tors that coordinate the establishment of pluripotency; (5) epige-
netic regulators, DNA repair proteins, and components of the
basal transcriptional and translational machinery that modulate
the kinetics of reprogramming.
Roadmaps of Epigenetic Reprogramming: Surface
Markers and Reporter Genes that Enable Kinetic
Analyses
Efforts to elucidate the sequence of molecular events during re-
programming have focused on three key events: (1) the initial
transcriptional and epigenetic changes resulting from the720 Cell Stem Cell 14, June 5, 2014 ª2014 Elsevier Inc.expression of ectopic reprogramming factors, (2) the transitions
through intermediate states that can be redirected toward alter-
native somatic destinations, and (3) the activation of a self-sus-
taining endogenous pluripotency circuitry. The heterogeneous
and asynchronous nature of reprogramming necessitates the
use of cell surfacemarkers or reporter alleles to isolate pure pop-
ulations of cells at each step. Here we review how different
markers have been used to lay down roadmaps of epigenetic re-
programming (Figure 1) and the extent to which these markers
can predict the successful outcome of reprogramming. We
also evaluate different models of the kinetics of reprogramming.
Temporal analyses of reprogramming typically distinguish
subpopulations based on the disappearance of surface markers
expressed in fibroblasts and emergence of surface markers
specific to pluripotent cells. Further resolution can be obtained
by integrating a fluorescent reporter associated with an endoge-
nous pluripotency determinant, such as Oct4 or Nanog. Initial
studies using doxycycline (dox)-inducible Oct4, Sox2, Klf4, and
c-Myc (collectively these are referred to as OSKM) transgenes
reported that the cell surface marker alkaline phosphatase (AP)
was activated prior to stage-specific embryonic antigen 1
(SSEA1), while Oct4-GFP and Nanog-GFP reporters were
induced later, concomitant with the loss of transgene depen-
dence (Brambrink et al., 2008). An accompanying study reported
that the surface antigen Thy1, which is highly expressed in fibro-
blasts, was downregulated prior to the onset of SSEA1 expres-
sion (Stadtfeld et al., 2008). Transcriptional and proteomic
analyses of subpopulations marked by Thy1, SSEA1, and
Oct4-GFP status identified two major waves of gene activity
(Figure 1A) (Hansson et al., 2012; Polo et al., 2012). The first
wave, between days 0 and 3, involves upregulation of genes
related to cell proliferation, metabolism, and cytoskeletal organi-
zation, while developmental genes were downregulated. A sec-
ond wave of gene activity occurred after day 9 in SSEA1+ cells
and was associated with a marked increase in pluripotency-
associated genes. Gene expression analysis of Thy1+ cells that
persisted beyond day 3 indicated that a failure to downregulate
mesenchymal genes was a signature of cells that became refrac-
tory to reprogramming shortly after dox treatment (Polo et al.,
AB
Figure 1. Roadmaps of Epigenetic
Reprogramming
(A) Trajectory of reprogramming intermediates
defined by Thy1, SSEA1, and Oct4-GFP (OGFP)
expression (Polo et al., 2012).
(B) Trajectories of reprogramming intermediates
defined by CD44, ICAM1, and Nanog-GFP (NGFP)
expression (O’Malley et al., 2013). Double lanes
indicate transitions thatoccurat a higher frequency.
iPSC, induced pluripotent stem cell; MEF, mouse
embryonic fibroblast; MET, mesenchymal-epithe-
lial transition; OSKM, Oct4, Sox2, Klf4, and c-Myc.
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epithelial transition (MET) is a critical early event during induction
of pluripotency in fibroblasts (Li et al., 2010; Samavarchi-Tehrani
et al., 2010).
A caveat of this roadmap is that the great majority of SSEA1+
cells never become iPSCs. In addition, this surface antigen is het-
erogeneously expressed in embryonic stem cells (ESCs) and
iPSCs. An alternative roadmap to pluripotency was proposed
based on the emergence of the surface marker ICAM1, which
is uniformly expressed in pluripotent cells (O’Malley et al.,
2013). However, this surface marker is also expressed in about
50% of fibroblasts. To discriminate between cells at early, inter-
mediate, and late stages of reprogramming, this study also
considered expression of the surface marker CD44 and a
Nanog-GFP reporter (Figure 1B). Dox-mediated induction of
OSKM resulted in the gradual disappearance of CD44+/ICAM1
cells and appearance of CD44/ICAM1+ cells around day 6.
Notably, some Nanog-GFP+ cells were detected even earlier.
By sorting subpopulations on day 10 based on the expression
of CD44, ICAM1, andNanog, the authors predicted the efficiency
of distinct transitions between these subpopulations. This re-
vealed that few cells were capable of activating Nanog-GFP
within a 24 hwindow. However, Nanog-GFP+ cells had a superior
capacity to generate iPSCs compared to Nanog-GFP cells with
the same CD44/ICAM1 profile. Thus, it was concluded that acti-
vation of Nanog is a rate-limiting step during iPSCs generation.
Expression profiling along the CD44/ICAM1/Nanog roadmap
revealed two notable trends. First, a cohort of endogenous plu-Cell Stem Ceripotency genes (including Oct4, Sall1,
and Sall4) was already significantly acti-
vated by the time cells had reached the
early signpostsmarked by disappearance
of CD44 expression or appearance of
Nanog-GFP activity (Figure 1B). Second,
O’Malley and colleagues observed a
transient up- and downregulation of
epidermal genes in intermediate states.
This trend was also observed in prior
expression analyses of partially reprog-
rammed cells (Mikkelsen et al., 2008;
Sridharan et al., 2009), a time course anal-
ysis of bulk populations during reprog-
ramming (Samavarchi-Tehrani et al.,
2010), and the Thy1/SSEA1/Oct4 road-
map (Polo et al., 2012). These findings
highlight gene expression dynamics thatwould not be expected a priori during the conversion of fibro-
blasts into iPSCs, revealing an unanticipated complexity to the
process of epigenetic reprogramming.
An investigation of population-level chromatin dynamics
during the initial stages of reprogramming reported the
genome-wide redistribution of histone H3 lysine 4 dimethylation
(H3K4me2), a mark associated with euchromatin, at thousands
of loci (Koche et al., 2011). In comparison, little change was
observed in the distribution of histone H3 lysine 27 trimethylation
(H3K27me3), a transcriptional-silencing-associated marker,
except for highly localized depletion at promoters that acquired
histone H3 lysine 4 trimethylation (H3K4me3), an activation-
associated marker. On the roadmap defined by Thy1/SSEA1/
Oct4 status, fluctuations between activating and repressive his-
tone modifications largely followed the observed ‘‘biphasic’’
change in transcriptional status (Polo et al., 2012). For example,
silencing of fibroblast-specific genes was accompanied by
acquisition of H3K27me3, whereas activation of pluripotency
genes was accompanied by the loss of H3K27me3 and acquisi-
tion of H3K4me3. In agreement with the study of population-level
chromatin dynamics (Koche et al., 2011), genes that were acti-
vated early already carried H3K4me3 marks in fibroblasts. In
contrast, reorganization of the DNA methylation landscape was
not observed until the later phase of reprogramming (Polo
et al., 2012). In accordance, genes involved in DNA methylation
and demethylation, such as the de novo methyltransferases
Dnmt3a and Dnmt3L, Apobec, and the 5-methylcytosine hy-
droxylase Tet1, were not upregulated until after day 9.ll 14, June 5, 2014 ª2014 Elsevier Inc. 721
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Figure 2. Models of Epigenetic Reprogramming
(A–D) Kinetics of reprogramming are graphically represented as a function of
latency and the cumulative proportion of donor cells that gives rise to iPSCs.
Latency indicates absolute time or the number of cell divisions. (A) Numerical
modeling during OSKM-mediated reprogramming of secondary B cells
demonstrated that induced pluripotency is essentially stochastic, but
amenable to acceleration by cell-division-rate-dependent modifications such
as overexpression of Lin28 or disruption of the p53/p21 pathway or a
cell-division-rate-independent modification such as overexpression of Nanog
(Hanna et al., 2009). (B) Deterministic model of reprogramming whereby
somatic cells transit to pluripotency with a fixed latency. This type of re-
programming has only been observed by overexpression of C/EBPa (Di Ste-
fano et al., 2013) or with the use of highly cycling donor cells (Guo et al., 2014).
Deterministic reprogramming was also observed upon elimination of Mbd3
(Rais et al., 2013), but a recent study concluded that Mbd3 has a beneficial
effect during the reprogramming process (dos Santos et al., 2014). (C) Model
of reprogramming inferred from single-cell expression profiling (Buganim et al.,
2012). (D) Biphasic model of reprogramming inferred from gene expression
profiling along the Thy1/SSEA1/Oct4-GFP roadmap (Polo et al., 2012).
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quirements of individual reprogramming factors? c-Myc targets
were predominantly regulated during the first wave of gene ac-
tivity, while common targets of the Oct4-Sox2 complex were
gradually activated later (Polo et al., 2012). This pattern corrob-
orates a previous study that identified c-Myc as the predomi-
nant inducer of early changes in gene expression by express-
ing each factor individually in fibroblasts (Sridharan et al.,
2009). Somewhat surprisingly, Klf4 targets were regulated
both during the early and late phases (Polo et al., 2012). This
finding suggests that, in addition to its established function in
promoting the activation of the pluripotency network (Hall
et al., 2009), Klf4 contributes actively to the early phase of re-
programming. It appears that this early role can be explained,
at least in part, by promoting gene expression changes associ-
ated with MET. Bone morphogenetic proteins (BMPs), which
also promote MET during the early phase of reprogramming
(Samavarchi-Tehrani et al., 2010), could replace Klf4 and722 Cell Stem Cell 14, June 5, 2014 ª2014 Elsevier Inc.induce pluripotency in fibroblasts with Oct4 alone (Chen
et al., 2011).
While both roadmaps provide enhanced resolution compared
to bulk population analyses, it is important to bear in mind that
neither study described markers that were fully capable of pre-
dicting the outcome of the reprogramming process. Hochedlin-
ger and colleagues point out that the surface markers c-Kit,
EpCAM, and PECAM1 become activated at successive time
points in SSEA1+ cells and may further enrich for intermediates
with the potential to form iPSCs (Polo et al., 2012). However, it
is likely that the expression of one or more transcriptional deter-
minants of pluripotency will be needed to identify cells with the
capacity to reprogram in a purely deterministic fashion. Quanti-
tative analysis of gene expression in single cells (Fluidigm) and
single-molecule RNA FISH techniques revealed that expression
of Esrrb, Utf1, Lin28, or Dppa2 is a better predictor of progres-
sion to pluripotency than previously suggested markers,
including Oct4 (Buganim et al., 2012). Thus, the identification
of a truly predictive set of markers may require the use of novel
reporter alleles. In this regard it is important to point out that re-
porter-based assessment of gene expression in pluripotent cells
can be significantly influenced by the genetic background and
gene-targeting strategy. For example, heterozygous loss-of-
function knockin reporters do not faithfully reflect expression of
Nanog in mouse ESCs (Faddah et al., 2013; Filipczyk et al.,
2013). The use of self-cleaving fluorescent reporters down-
stream of coding sequences reduces the risk of altering endog-
enous transcriptional control mechanisms.
Several models have been proposed to explain the kinetics of
reprogramming. The stochastic model holds that pluripotency is
acquired as a result of the random occurrence of one or more
rate-limiting steps. Consequently, iPSCs are generated with var-
iable latencies (Figure 2A). In contrast, the deterministic model
posits that reprogramming proceeds through a defined order of
events with fixed latency (Figure 2B). Numerical modeling
demonstrated that OSKM-mediated reprogramming is essen-
tially stochastic, but amenable to acceleration by modifications
such as inhibition of the p53/p21 pathway and overexpression
of Lin28 or Nanog (Hanna et al., 2009). Analyses of single cells
(Buganim et al., 2012) and intermediate subpopulations (Polo
et al., 2012) indicated that distinct phases of the reprogramming
process are associated with stochastic or deterministic changes
in gene expression. The studies reached different conclusions
regarding the timing of these phases: single-cell analysis re-
vealed that early changes in gene expression are largely stochas-
tic, while the later stages follow a deterministic order of events
startingwith activation of endogenousSox2 (Figure 2C) (Buganim
et al., 2012). This deterministic phase of reprogramming appears
to coincide with the stabilization phase described by Wrana and
colleagues, during which repression of OSKM transgenes allows
full expression of the pluripotency network (Golipour et al., 2012).
On the other hand, the roadmap defined by Thy1/SSEA1/Oct4
expression identified two major waves of gene activity at the
beginning and end of reprogramming, with a predominantly sto-
chastic phase observed in between (Figure 2D) (Polo et al., 2012).
As we discuss later, the efficiency of reprogramming, however,
can be dramatically enhanced by the removal of specific barriers
to induced pluripotency, challenging previous assumptions
about the stochastic nature of reprogramming.
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Yamanaka’s Cocktail
Starting with a pool of 24 candidate factors, Yamanaka used a
process of elimination to identify OSKM as the original reprog-
ramming cocktail in mouse fibroblasts (Takahashi and Yama-
naka, 2006). We now know that there is remarkable flexibility in
the choice of defined factors that can induce pluripotency
(Figure 3A). Here we reconstruct how Yamanaka’s cocktail of
defined factors has been modified over time and how this in-
forms our understanding of the reprogramming process.
One of the first modifications was to reprogram fibroblasts into
iPSCs using Oct4, Sox2, and Klf4 (OSK) alone (Nakagawa et al.,
2008; Wernig et al., 2008). However, the three-factor reprogram-
ming process was significantly delayed compared to cells also
transduced with the oncogene c-Myc. In hindsight, including
c-Myc was a stroke of genius that made the process sufficiently
efficient to detect the first iPSCs in culture. The role of c-Myc re-
mains a subject of debate, but its dominant role during the early
phase of reprogramming is widely recognized (Polo et al., 2012;
Sridharan et al., 2009). Compared to target genes of OSK, tar-
gets of c-Myc are strongly associated with an active chromatin
signature in mouse ESCs (Kim et al., 2008). It is also known
that c-Myc regulates transcriptional pause release at a third of
all actively transcribed genes in ESCs (Rahl et al., 2010). There-
fore, c-Myc may enhance the efficiency of iPSC generation by
transcriptional amplification of genes involved in cellular prolifer-
ation. Zaret and colleagues reported that OSK act as pioneer
factors for c-Myc at distal elements and promoters with closed
chromatin and that binding by the reprogramming factors is
not predominantly dictated by pre-existing open histone modifi-
cations (Soufi et al., 2012). This study assigned a direct role to
c-Myc in facilitating the initial engagement of OSK with many
chromatin sites.
Each of the original Yamanaka factors can be replaced by
other transcription factors. This attribute has revealed a high de-
gree of redundancy among the genetic factors capable of
inducing pluripotency. As might be expected from their struc-
tural similarity, homologs of Klf4, Sox2, and c-Myc had reprog-
ramming activity in mouse fibroblasts (Nakagawa et al., 2008).
Klf4 and c-Myc were replaced by the combination of Nanog
and Lin28 in human fibroblasts (Yu et al., 2007) and by the orphan
nuclear receptor Esrrb in mouse fibroblasts (Feng et al., 2009).
Nanog and Esrrb may operate through similar mechanisms as
Esrrb is a direct transcriptional target of Nanog that, like Nanog,
can maintain self-renewal of mouse ESCs in the absence of leu-
kemia inhibitory factor (LIF) signaling (Festuccia et al., 2012).
Another orphan receptor, Nr5a2, and to a lesser extent, Nr5a1,
replaced the requirement for exogenous Oct4, but this likely oc-
curs through activation of endogenous Oct4 (Heng et al., 2010).
Oct4 can also be replaced by E-cadherin, a master regulator of
the epithelial phenotype (Redmer et al., 2011). The underlying
mechanism is unclear, but E-cadherin overexpression prevents
the nuclear localization of b-catenin, a negative regulator of the
early phase of reprogramming (Ho et al., 2013).
The repertoire of transcription factors capable of inducing plu-
ripotency was further expanded by single-cell expression anal-
ysis of 48 genes during reprogramming (Buganim et al., 2012).
A Bayesian network was derived by monitoring multiple clonally
related single sister cells at different time points. This modelholds that activation of endogenous Sox2 initiates a series of
consecutive steps leading to the activation of many pluripotency
genes. According to this analysis, Sox2 first turns on Sall4, which
then activates four downstream targets, including Oct4. This
hierarchical model of gene activation predicted combinations
of transcription factors that did not include Oct4 or Sox2, but
were capable of inducing pluripotency. Furthermore, this study
identified two combinations of four factors that could replace
OSKM entirely: Sall4, Esrrb, and Lin28 combined with either
Dppa2 or Nanog (Buganim et al., 2012).
Methodologies to induce cell fate conversion typically use
transcription factors, rather than chromatin-modifying enzymes,
to initiate reprogramming. However, several studies have identi-
fied epigenetic regulators that can replace some of the Yama-
naka factors, directly highlighting epigenetic remodeling events
of functional importance for induced pluripotency. These regula-
tors include the corepressor Rcor2 (Yang et al., 2011), the
5-methylcytosine (5mC) hydroxylase Tet1 (Gao et al., 2013),
and the histone variants TH2A and TH2B (Shinagawa et al.,
2014). In addition, some Yamanaka factors can be replaced by
the removal of epigenetic barriers to reprogramming. For
example, human fibroblasts can be reprogrammed by Oct4
and Sox2 alone after knockdown of DOT1L, the histone H3 lysine
79 (H3K79) methyltransferase (Onder et al., 2012). DOT1L inhibi-
tion facilitated the loss of H3K79 dimethylation (H3K79me2), an
activation-associated marker, from fibroblast genes associated
with the epithelial-to-mesenchymal transition (EMT). Further-
more, DOT1L was downregulated by the Toll-like receptor 3
(TLR3) pathway, which may facilitate reprogramming by stimu-
lating the innate immune response (Lee et al., 2012).
A subset of the microRNA (miR)-290 cluster, called the ESC-
specific cell cycle (ESCC)-regulating miRNAs, enhanced the ef-
ficiency of reprogramming by OSK and may be a downstream
target of c-Myc (Judson et al., 2009). Surprisingly, two groups re-
ported that overexpression of some miRNAs can replace tran-
scriptional inducers of pluripotency altogether (Anokye-Danso
et al., 2011; Miyoshi et al., 2011). miRNAs promote reprogram-
ming through multiple mechanisms, including the blocking of
TGF-b-induced EMT and regulation of cell cycle-related genes
(Liao et al., 2011; Subramanyam et al., 2011). In addition, the
miRNAsmiR-205 andmiR-200 family members were implicated
in the promotion of MET during the early phase of reprogram-
ming in response to BMP signaling (Samavarchi-Tehrani et al.,
2010). Yamanaka and colleagues demonstrated that some
miRNAs have an opposite effect on the reprogramming process
(Worringer et al., 2014). Specifically, this study reported that let-7
miRNAs inhibit the expression of LIN-41, a translational
repressor of the prodifferentiation gene EGR1. An antisense
inhibitor of let-7 increased the efficiency of OSK-induced reprog-
ramming of human fibroblasts by one or two orders of magni-
tude, achieving an efficiency similar to that observed with
OSKM. Finally, miRNAs can also serve as signposts of the re-
programming process, delineating alternative paths to induced
pluripotency. Blelloch and colleagues targeted fluorescent re-
porters into the miR-290 and miR-302 clusters and tracked the
activation of these two miRNAs during somatic cell reprogram-
ming (Parchem et al., 2014). This analysis revealed that a cell’s
trajectory is dependent on the choice of reprogramming factors:
whereas miR-290 and miR-302 were activated in a stochasticCell Stem Cell 14, June 5, 2014 ª2014 Elsevier Inc. 723
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were activated sequentially when Sall4 was included in the cock-
tail of defined factors.
Most of the inducers of pluripotency discussed thus far are
factors that are highly expressed in ESCs. Two studies reported
that Oct4 and Sox2 could be replaced by lineage specifiers that
are not enriched in ESCs. Deng and colleagues identified Gata3
as an unexpected Oct4 replacer by screening a plasmid library
(Shu et al., 2013). Gene expression analysis showed that viral
infection of Oct4 and Gata3 in fibroblasts inhibits the expression
of a set of ectodermal specification (ECT)-related genes that are
elevated by Sox2, Klf4, and c-Myc. The authors then investi-
gated whether other mesendodermal (ME) lineage specifiers
could induce a similar transcriptional response, identifying
Gata6, Sox7, Pax1, Gata4, C/EBPa, HNF4a, and Grb2 as alter-
native Oct4 replacers. Sox2 and its reprogramming substitutes,
Sox1, Sox3, and Gmn, attenuated the induction of ME genes af-
ter infection with Oct4, Klf4, and c-Myc. Remarkably, multiple
combinations of ECT and ME specifiers were able to replace
Oct4 and Sox2 simultaneously (Shu et al., 2013). Similar results
were described during reprogramming of human fibroblasts to
pluripotency (Montserrat et al., 2013). This finding led to the
proposition of the ‘‘seesaw’’ model, which holds that a somatic
cell has greater potential of reaching pluripotency when it is
balanced by two opposing differentiation potentials.
Insights from Chemical Reprogramming
An important objective of current work in epigenetic reprogram-
ming is to develop transgene-free methodologies for inducing
pluripotency. These approaches lay the foundation for safer
and more accessible reprogramming technologies that would
be suitable for human therapeutic applications. Some of these
studies have implicated previously unsuspected signaling path-
ways and epigenetic mechanisms in the induction of pluripo-
tency, often after screening extensive collections of small mole-
cules. Here we review the most promising chemical approaches
to reprogramming and discuss the underlying mechanisms.
Initial reports described chemicals that facilitate the transition
to pluripotency in stable reprogramming intermediates, including
the DNA methyltransferase inhibitor 5-aza-cytidine (Mikkelsen
et al., 2008) and the 2i cocktail, which consists of the MEK inhib-
itor PD0325901 and GSK3 inhibitor CHIR99021 (Silva et al.,
2008). Several groups have shown that 2i induces global hypo-
methylation in pluripotent cells by induction of Prdm14, which
in turn causes the downregulation of de novo DNA methyltrans-
ferases (see the Review in this issue by Lee et al. [2014]). These
observations suggest that 5-aza-cytidine and 2i may promote
the final stages of reprogramming through partially overlapping
epigenomic mechanisms. Smith and colleagues have shown
that GSK3 inhibition promotes the self-renewal of ESCs byFigure 3. Methodologies for Inducing Pluripotency
(A) Transgene-mediated reprogramming strategies: 1Takahashi and Yamanaka, 2
2010; 6Maekawa et al., 2011; 7Buganim et al., 2012; 8Mansour et al., 2012; 9Redm
13Onder et al., 2012; 14Kawamura et al., 2009; 15Tahmasebi et al., 2014; 16Judso
et al., 2011; 20Shu et al., 2013; 21Montserrat et al., 2013.
B) Chemical reprogramming strategies: 22Huangfu et al., 2008a; 23Huangfu et a
27Chen et al., 2011; 28Maherali and Hochedlinger, 2009; 29Ichida et al., 2009; 30H
gray. This is not an exhaustive list of factor and chemical combinations, but only
mainly performed in fibroblasts, and transgene requirements may be different foremoving the repressive influence of Tcf3 on the expression of
Esrrb (Martello et al., 2012). Therefore, another plausible mech-
anism underlying the effect of GSK3 inhibition is the activation
of Esrrb, a component of several reprogramming factor cocktails
(Figure 3A) (Buganim et al., 2012; Feng et al., 2009).
Chemical screens have identified compounds that replace in-
dividual Yamanaka factors during iPSC generation (Figure 3B).
Melton and colleagues reported that histone deacetylase
(HDAC) inhibitors, such as valproic acid (VPA), enabled efficient
reprogramming of mouse fibroblasts in the absence of c-Myc
(Huangfu et al., 2008a) and human fibroblasts in the absence
of both c-Myc and Klf4 (Huangfu et al., 2008b). A different screen
identified the GSK3-b and CDK inhibitor kenpaullone (KP) as a
replacer of Klf4 (Lyssiotis et al., 2009). However, its effect was
not phenocopied by other GSK3-b andCDK inhibitors, indicating
that KP has a different mode of action. Inhibition of TGF-b
signaling was capable of activating endogenous Nanog and re-
placing the requirement for ectopic Sox2 and c-Myc (Ichida
et al., 2009; Maherali and Hochedlinger, 2009). Since TGF-b
signaling is activated during ME specification, this result lends
further support to the hypothesis that Sox2 represses ME genes
during reprogramming, a central tenet of the seesaw model
(Montserrat et al., 2013; Shu et al., 2013).
Vitamin C enhanced the induction of pluripotency in murine
and human fibroblasts (Esteban et al., 2010). The underlying
mechanisms have been the focus of several studies. Vitamin C
reduced histone 3 lysine 36 dimethylation and trimethylation
(H3K36me2/3) levels by potentiating the demethylases
Jhdm1a/1b (Wang et al., 2011). Specifically, Jhdm1b (also
known as Kdm2b) suppressed cell senescence by removing
H3K36me2/3 marks from the Ink4/Arf locus, resulting in its tran-
scriptional silencing. In addition, the removal of H3K36me2/3
marks from themiR-302/367 cluster by Jhdm1b facilitated bind-
ing and activation by Oct4. Thus, changes in this histone modifi-
cation mark are associated with both gene activation and gene
repression. The important role of these histone demethylases
was underscored by the observation that forced expression of
Jhdm1a replaced Klf4 and c-Myc, while Jhdm1b replaced
Sox2, Klf4, and c-Myc in the presence of vitamin C (Wang
et al., 2011). Jhdm1b was also shown to have an alternative,
vitamin C-independent role by contributing to activation of early
responsive genes during reprogramming through its H3K36 de-
methylase domain (Liang et al., 2012).
Loss of imprinting at the Dlk1-Dio3 locus was reported to
reduce the efficiency with which iPSCs contribute to ‘‘all-iPSC’’
mice by tetraploid (4n) complementation (Stadtfeld et al.,
2010). Another study found, however, that competence to form
all-iPSC mice was primarily dependent on the stoichiometry
of reprogramming factor expression (Carey et al., 2011).
Hochedlinger and colleagues reported that chemical treatment006; 2Yu et al., 2007; 3Nakagawa et al., 2008; 4Feng et al., 2009; 5Heng et al.,
er et al., 2011; 10Yang et al., 2011; 11Shinagawa et al., 2014; 12Gao et al., 2013;
n et al., 2009; 17Worringer et al., 2014; 18Anokye-Danso et al., 2011; 19Miyoshi
l., 2008b; 24Lyssiotis et al., 2009; 25Esteban et al., 2010; 26Wang et al., 2011;
ou et al., 2013; 31Zhu et al., 2010. Original Yamanaka factors are colored light
includes those methods highlighted in the text. Note that these studies were
r other types of somatic donor cells, such as neural stem cells.
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programming of B lymphocytes into iPSCs with 4n capability
(Stadtfeld et al., 2012). The effect of vitamin C was attributed
to preserved imprinting in theDlk-Dio3 locus by themaintenance
of H3K4me2 and acquisition of H3K4me3. These histone modi-
fications prevented binding of Dnmt3a, which is essential for
Dlk1-Dio3DNA hypermethylation but can only recognize unmod-
ified H3K4 tails.
Combined inhibition of intracellular signaling and epigenetic
remodeling enables the replacement of multiple Yamanaka fac-
tors simultaneously. However, replacement of Oct4 long re-
mained a stumbling block on the road toward chemically
induced pluripotent cells. Deng and colleagues performed
high-throughput chemical screening to successfully identify
several Oct4 replacers, including the cyclic AMP agonist forsko-
lin (FSK) (Hou et al., 2013). When FSK was used in conjunction
with a cocktail of inhibitors previously reported to support
Oct4-induced reprogramming, the authors were able to derive
germline-competent iPSCs without the use of transgenes. Four
essential small molecules were identified: FSK, the GSK3 inhib-
itor CHIR990291, the TGF-b inhibitor 616452, and DZNep, an
S-adenosylhomocysteine (SAH) hydrolase inhibitor. While the
mechanisms underlying this chemical reprogramming method
remain incompletely understood, it is clear that these com-
pounds activate several inducers of pluripotency. In particular,
chemical treatment stimulated the expression of Gata4, Gata6,
Sall4, Sox2, and Sox17. The inclusion during the final stages of
reprogramming of DZNep, which represses S-adenosylmethio-
nine (SAM)-dependent cellular methylation events, decreased
DNA methylation and H3K9 methylation levels at the Oct4 pro-
moter (Hou et al., 2013).
So far these conditions have not been successfully applied to
the chemical reprogramming of human somatic cells into iPSCs.
However, some progress has been reported with chemical
reprogramming in human cells. OCT4-induced reprogramming
of human primary somatic cells was achieved by combining
TGF-b inhibition, HDAC inhibition, and MEK inhibition with a
small molecule activator of 30-phosphoinositide-dependent
kinase-1 (PDK1) (Zhu et al., 2010). Therefore, the successful gen-
eration of chemically induced, patient-specific iPSCs may be
contingent on identifying druggable activators ofOCT4 in human
cells.
Inducing Novel States of Pluripotency
Human ESCs and iPSCs exhibit molecular and biological proper-
ties similar to epiblast stem cells (EpiSCs) derived from the
mouse postimplantation epiblast. These cells express pluripo-
tency genes such as Oct4, Sox2, and Nanog, but only rarely
contribute to chimeric mice after blastocyst injection (Brons
et al., 2007; Tesar et al., 2007). This limitation has led to the sug-
gestion that EpiSCs represent a ‘‘primed’’ state of pluripotency,
as opposed to the ‘‘naive’’ state of mouse ESCs (Nichols and
Smith, 2009). An important aim of current research is to define
the state of pluripotency and to assess whether human ESCs
can be induced into the naive state. Several studies described
small molecules that induce a naive-like state in conventional hu-
man ESCs. Hanna and colleagues reported that a medium
comprising inhibitors of Jun kinase and p38 MAP kinase in addi-
tion to 2i, LIF, FGF, and TGF-b induces naive properties in human726 Cell Stem Cell 14, June 5, 2014 ª2014 Elsevier Inc.ESCs (Gafni et al., 2013). These cells had a globally altered chro-
matin profile, including reduced levels of H3K27me3 at develop-
mental genes and a global reduction in poised enhancers
marked by the presence of H3K4me1 and H3K27me3 and the
absence of H3K27ac. Remarkably, human iPSCs cultured
under these conditions made a contribution to chimeric embryos
after injection into mouse morulae. Another study described the
isolation of naive-like human ESCs by culture in mTeSR1
medium, which contains high levels of FGF, supplemented
with PD0325901, the GSK3 inhibitor BIO, LIF, and Dorsomor-
phin, an inhibitor of BMP signaling (Chan et al., 2013). Under
these conditions OCT4 and NANOG occupied a significantly
different set of target genes. In addition, derivation of human
ESCs in 2i and FGF generated cells with a similar expression pro-
file as previously reported transgene-dependent naive-like
human ESCs (Ware et al., 2014). Surprisingly, all of these studies
observed a requirement for FGF, which in the mouse system
stimulates differentiation into the primed state. Additional path-
ways involved in the establishment and maintenance of naive
human pluripotency may yet be identified through high-
throughput chemical screening. It will also be of interest to
explore whether human ESCs display a dynamic equilibrium be-
tween naive and primed states, as has been described by Surani
and colleagues in single mouse ESCs based on the heteroge-
neous expression of Stella (Hayashi et al., 2008).
A recent study suggested that exposure of murine somatic
cells to stress, such as low pH, may induce a novel state of plu-
ripotency with the potential to contribute to both embryonic and
placental tissues (Obokata et al., 2014). This work has received
intense scrutiny in recent months due to lack of reproducibility.
However, an expanded fate potential was previously observed
in subpopulations of mouse ESCs. Pfaff and colleagues reported
that ESCs fluctuate through a totipotent ‘‘two-cell-like’’ state,
which is characterized by global enrichment in activation-associ-
ated histone marks and hypomethylation at endogenous
retroviral (ERV) elements (Macfarlan et al., 2012). In addition,
Brickman and colleagues described heterogeneous expression
of the extraembryonic endoderm marker Hex in mouse ESCs
cultured in 2i + LIF. Purified Hex-positive ESCs contributed effi-
ciently to both the epiblast and all extraembryonic lineages
following morula aggregation (Morgani et al., 2013). This
expanded differentiation potential was also observed upon in-
jection of single Hex-positive ESCs into morulae, providing evi-
dence of totipotency at the single-cell level. Unlike two-cell-like
ESCs marked by ERV expression, Hex-positive ESCs continued
to express core pluripotency genes, including Oct4, Sox2, and
Nanog. Future experimental work is needed to examine conclu-
sively whether totipotent cells can be induced directly from
somatic cells through environmental stimuli, chemical manipula-
tion, or other means.
The question of whether iPSCs retain characteristics of their
somatic origin has been a subject of considerable interest. While
low-passage iPSCs may exhibit some epigenetic memory (Kim
et al., 2010), extended passaging brought the methylation pat-
terns of iPSCs closer to ESCs (Nishino et al., 2011; Polo et al.,
2010). In addition, the effect of subtle variations in culture
methods between laboratories appears to overshadow any
consistent gene expression differences between human iPSCs
and ESCs (Newman and Cooper, 2010), which also display little
Figure 4. Gatekeepers of Pluripotency
Requirements of the master transcription factors
Oct4 andNanog during epigenetic reprogramming
events in the mouse system in vitro and in vivo.
Broken lines indicate cell fate transitions where the
role of Oct4 or Nanog is contested (see text for
details). ESCs, embryonic stem cells; EpiSCs,
epiblast stem cells; SCNT, somatic cell nuclear
transfer; 2i, cocktail of MEK and GSK3 inhibitors.
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H3K27me3 (Guenther et al., 2010). We conclude that reprogram-
ming with the Yamanaka factors under conventional conditions
induces a state of pluripotency that is indistinguishable from
ESCs for all practical purposes.
Gatekeepers of Pluripotency
While ‘‘drivers’’ of epigenetic reprogramming have received the
lion’s share of research interest, an important function is
performed by endogenous master transcription factors whose
upregulation controls entry to the pluripotent state. The best-
characterized ‘‘gatekeepers’’ of pluripotency also serve as
potent inducers or facilitators of reprogramming when ectopi-
cally expressed. However, the effects of overexpressing a tran-
scription factor in fibroblasts must be discriminated from the role
of its endogenous gene product during the later stages of iPSC
induction. Loss-of-function experiments have traced the genetic
requirements of two central pluripotency determinants, Oct4 and
Nanog, during epigenetic reprogramming events in vivo and
in vitro (Figure 4).
The POU family transcription factor Oct4 is required for the for-
mation of pluripotent cells in the mouse embryo and the deriva-
tion of ESCs (Nichols et al., 1998). Oct4 is also continuously
expressed throughout primordial germ cell (PGC) specification,
and conditional deletion of Oct4 in PGCs caused apoptosis as
early as E10 (Kehler et al., 2004). Early studies in mouse ESCs
indicated that the dosage of Oct4 tightly controls cell fate asCell Stem Celoss of Oct4 caused differentiation to the
trophectoderm lineage, while elevated
Oct4 expression resulted in differentiation
into cells expressing endoderm and
mesoderm markers (Niwa et al., 2000).
In addition, a reduced expression level
of exogenousOct4 arising from subtle dif-
ferences in polycistronic vector design
affected the quality of iPSCs (Carey
et al., 2011).
To further flesh out the dose-depen-
dent role of Oct4 during induced pluripo-
tency, Silva and colleagues reprog-
rammed Oct4/ somatic cells with a
piggyBac vector containing bicistronic
Oct4 andCherry sequences (Radzisheus-
kaya et al., 2013). This revealed that
transition through the initial stages of re-
programming involved a range of Oct4
expression levels, while the resulting
iPSCs invariably exhibited an ESC-level
of Oct4. Consistent with this observation,high levels of OSKM transgene expression were detrimental dur-
ing the final stage of reprogramming (Golipour et al., 2012). Once
pluripotency was established, however, a 7-fold reduction
in Oct4 expression did not cause the loss of self-renewal or
downregulation of other core regulators, such as Nanog. In
fact, Oct4-low iPSCs exhibited reduced responsiveness to dif-
ferentiation-inducing signals (Radzisheuskaya et al., 2013),
which was also observed in Oct4+/ ESCs (Karwacki-Neisius
et al., 2013). Biochemically, reduced expression of Oct4 was
associated with enhanced LIF sensitivity, upregulation of Wnt
signaling ligands, and increased binding of Nanog to key target
genes. Remarkably, differentiation into all three embryonic line-
ages was observed with iPSCs that constitutively expressed
an ESC-level of Oct4, but not a reduced level of Oct4 (Radzish-
euskaya et al., 2013). This finding suggests that Oct4 has a pre-
viously unappreciated role in cellular differentiation.
Do other methods for inducing epigenetic reprogramming
also require Oct4? Surprisingly, oocytes deficient in maternal
Oct4 were fully capable of reprogramming somatic cells by
nuclear transfer (Wu et al., 2013). Furthermore, embryos defi-
cient in both maternal and zygotic Oct4 still initiated lineage
segregation between trophectoderm and the inner cell mass
(ICM) at E3.5, but could not support the subsequent develop-
ment of a viable naive pluripotent epiblast (Wu et al., 2013).
Hence, genetic studies suggest there are distinct requirements
for Oct4 during the establishment of totipotent and pluripotent
cells.ll 14, June 5, 2014 ª2014 Elsevier Inc. 727
Figure 5. An Interactome of Reprogramming Factors
Protein-protein interactions between reprogramming factors (blue) and
epigenetic modifiers (red) implicated in the induction of pluripotency. Red
borders indicate the original Yamanaka factors. Interaction data was curated
from interactome studies in mouse ESCs (Costa et al., 2013; Ding et al., 2012;
Gagliardi et al., 2013; Gao et al., 2012; Wang et al., 2006) and additional
studies described in the text. Superimposed on the interactome are regulatory
relationships inferred from single-cell analysis during reprogramming (yellow
arrows) (Buganim et al., 2012).
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required for the establishment of the naive pluripotent epiblast
in vivo and the derivation of ESCs (Chambers et al., 2003; Mitsui
et al., 2003; Silva et al., 2009). However, the role of Nanog in
maintenance of pluripotent cells was redefined by the observa-
tion that it could be permanently removed from ESCs without
compromising their ability to contribute to chimeric mice (Cham-
bers et al., 2007). Nevertheless, Nanog/ cells failed to develop
into germ cells beyond E11.5. This study also reported that
Nanog expression fluctuates, thereby predisposing a subset of
ESCs to differentiation. However, single-cell analysis showed
that expression of Nanog is equally variable as that of other plu-
ripotency-associated genes (Faddah et al., 2013; Filipczyk et al.,
2013). Unlike Oct4, Nanog was dispensable for the derivation
and maintenance of EpiSCs (Osorno et al., 2012). In addition,
the absence of a hypoblast in Nanog/ blastocysts was attrib-
uted to a non-cell-autonomous requirement for paracrine sup-
port from the epiblast (Messerschmidt and Kemler, 2010).
Thus, the requirement of Nanog appears to be restricted to the
establishment of naive pluripotency and germ cell development.
Both of these developmental transitions are associated with
widespread epigenetic remodeling events. In female embryos,
Nanog expression at E4.5 correlated precisely with the subset
of cells that show X chromosome reactivation (Silva et al.,
2009). Together with Oct4 and Sox2, Nanog was implicated in
the repression of the cis-acting, noncoding RNA Xist (Navarro
et al., 2008), suggesting that core pluripotency factors directly
contribute to X chromosome reactivation.
While Nanog was not included in Yamanaka’s original cocktail
of reprogramming factors, its potent effects during induced plu-
ripotency are widely documented. Nanog was used to repro-
gram human somatic cells to pluripotency (Yu et al., 2007) and
was present in several factor combinations that replaced the Ya-728 Cell Stem Cell 14, June 5, 2014 ª2014 Elsevier Inc.manaka factors (Buganim et al., 2012). In addition, overexpres-
sion of Nanog enhanced the efficiency of OSKM-mediated re-
programming (Hanna et al., 2009; Theunissen et al., 2011).
Endogenous Nanog was dispensable during the initial stages
of reprogramming, but required for establishment of pluripo-
tency in 2i conditions (Silva et al., 2009). Recent studies demon-
strated that the requirement of Nanog can be bypassed by
exogenous provision of its downstream effectors, phosphory-
lated (p)-STAT3 and Klf4 or Esrrb (Festuccia et al., 2012; Stuart
et al., 2014). This underscores the crucial role of LIF-STAT3
signaling during iPSC generation. In addition, vitamin C treat-
ment enabled the induction of pluripotency in Nanog/ somatic
cells (Schwarz et al., 2014), which puts a spotlight on the role of
Nanog in recruiting vitamin C-dependent Tet dioxygenases to
core pluripotency loci (Chen et al., 2013a; Costa et al., 2013).
Surprisingly, Eggan and colleagues reported that Nanog/
iPSCs generated at low efficiency with high titers of OSKM
made a contribution to the germline in chimeras produced by
blastocyst injection (Carter et al., 2014). Future studies will
need to resolve the precise extent of germline transmission in
the absence of Nanog and address the discrepancy with obser-
vations made using Nanog/ ESCs (Chambers et al., 2007).
Another point of interest will be to investigate X chromosome dy-
namics during Nanog-independent reprogramming.
The intimate role of Oct4 and Nanog in the establishment of
pluripotency has prompted interest in identifying their mecha-
nisms of action. Acute depletion of each factor in mouse ESCs
caused expression changes in a wide array of target genes,
demonstrating that Oct4 andNanog have a dual role in gene acti-
vation and repression (Loh et al., 2006). As we discuss below,
these ‘‘gatekeepers’’ of pluripotency serve as hubs in transcrip-
tion factor networks in ESCs, engaging with multiple different
epigenetic regulators. The importance of these cofactors is un-
derscored by the observation that a conserved linker region,
which serves as an interface for protein-protein interactions
with key epigenetic modifiers, was critical for the reprogramming
activity of Oct4 (Esch et al., 2013).
Modulators of Epigenetic Reprogramming
Perturbation of various epigenetic regulators influences the
kinetics of reprogramming. Many of these regulators are
directly recruited by the reprogramming factors to stimulate
the expression of core pluripotency genes. A network of pub-
lished protein-protein interactions between factors implicated
during iPSC generation reveals extensive interconnectivity be-
tween ‘‘drivers’’ and ‘‘modulators’’ of epigenetic reprogramming
(Figure 5).
Chromatin remodelers are key components of the interactome
of reprogramming factors. Combined overexpression of
ESC-specific BAF (esBAF) components Smarca4/Brg1 and
Smarcc1/BAF155 synergistically enhanced OSK-induced re-
programming of fibroblasts (Singhal et al., 2010). Mechanisti-
cally, these remodelers enhanced Oct4 binding to the Sall4,
Tcf3, andDppa4 promoters and increased the activation-associ-
ated markers H3K4me3 and H3K9 acetylation (H3K9ac) on Oct4
target genes. Both Brg1 and BAF155 form a direct physical inter-
action with Oct4 (Ding et al., 2012), and the interaction with Brg1
was mapped to the evolutionarily conserved Oct4 linker region
(Esch et al., 2013). A recent study demonstrated that binding
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actively expressed target genes from those repressed by the
master transcription factors in mouse ESCs (Wang et al.,
2014). Upon recruitment by Oct4 and the H3K4 methyltransfer-
ase complex component Wdr5, INO80 maintains nucleosome-
depleted regions and recruits Mediator and RNA Polymerase
II. Knockdown of INO80 reduced the efficiency of reprogram-
ming, while injection of short interfering RNAs against INO80 in
the one-cell embryo impaired blastocyst formation ex vivo.
This study illustrates how a chromatin remodeler can coordinate
input fromOct4 and a histonemethyltransferase to stimulate plu-
ripotency gene expression.
The role of Mbd3, the scaffold protein of the nucleosome re-
modeling and deacetylase (NuRD) complex, has received signif-
icant interest. Hanna and colleagues reported that depletion of
Mbd3 in mouse and human somatic cells enhanced the effi-
ciency of reprogramming to a deterministic level (Figure 2B)
(Rais et al., 2013). Mbd3 physically interacts with all four
OSKM factors, suggesting that recruitment of Mbd3 to down-
stream OSKM target genes may provide a ‘‘brake’’ on their re-
programming activity. However, treatment of human fibroblasts
with short hairpin RNAs (shRNAs) against MBD3 prior to OSKM
expression did not improve the efficiency of reprogramming (On-
der et al., 2012). More recently, Silva and colleagues reported
that genetic or siRNA-mediated depletion of Mbd3 had no
apparent effect during reprogramming of mouse fibroblasts,
and in fact reduced the efficiency of reprogramming in neural
stem cells (dos Santos et al., 2014). Furthermore, overexpres-
sion of Mbd3/NuRD enhanced the conversion of EpiSCs to naive
pluripotency in conjunction with Nanog. In contrast to this work,
Rais et al. (2013) used lentiviral reprogramming vectors and sec-
ondary somatic donor cells. While such technical and procedural
differences may account for subtle variation, the wide discrep-
ancy in phenotypic outcome between these studies is unex-
pected. It should be noted that deterministic reprogramming
was also observed upon OSKM activation in a subset of fast-
cycling bone marrow cells (Guo et al., 2014) or transient overex-
pression of C/EBPa followed by OSKM activation in primary B
cells (Di Stefano et al., 2014). These studies do not exclude the
possibility that deterministic reprogramming may be preceded
by a short stochastic phase. It is likely, however, that the largely
stochastic nature of Yamanaka’s original protocol is not inherent
to the process of induced pluripotency.
Histone methyltransferases and demethylases occupy a cen-
tral role in the control of induced pluripotency. Wdr5, a core
component of the Trithorax complex, was recruited by Oct4 to
mediate trimethylation of H3K4 at loci of pluripotency genes in
mouse ESCs (Ang et al., 2011). Knockdown of Wdr5 during the
initial stages of OSKM-mediated reprogramming reduced the ef-
ficiency of iPSC generation, suggesting that Oct4 recruits the
Trithorax complex to reconfigure the H3K4me3 signature in
somatic cells. Hanna and colleagues demonstrated that Oct4,
Sox2, and Klf4 engage with the histone demethylase Utx to re-
move the transcriptional-silencing-associated H3K27me3 mark
from target loci including Sall4, Sall1, and Utf1 (Mansour et al.,
2012). Overexpression of these target genes together with
c-Myc and Nanog provided an alternative to exogenous
OSK expression for induction of pluripotency in fibroblasts
(Figure 3A). B cells deficient in Utx acquired pluripotency withsignificantly reduced efficiency, as did primary human fibro-
blasts treated with short hairpin RNAs (shRNAs) against UTX.
Therefore, transcriptional inducers of reprogramming can asso-
ciate with both writers and erasers of histone marks to promote
the expression of downstream targets.
Several modulators of reprogramming converge on regulation
of the heterochromatic histone mark, H3K9 trimethylation
(H3K9me3). Megabase-scale H3K9me3-containing regions of
the genome were found to be refractory to OSKM binding in hu-
man fibroblasts (Soufi et al., 2012). In addition, H3K9methylation
at core pluripotency loci was identified as a major roadblock that
prevents murine reprogramming intermediates from reaching
the pluripotent state (Chen et al., 2013b; Sridharan et al.,
2013). Global H3K9me3 levels during reprogramming are the
outcome of a tug-of-war between vitamin C-dependent H3K9
demethylases and H3K9 methyltransferases, which are acti-
vated by BMPs in serum (Chen et al., 2013b). Plath and col-
leagues showed that inhibition of Cbx3, a reader of H3K9me3,
enhanced the efficiency of reprogramming (Sridharan et al.,
2013). The mechanism involves the repression of Nanog by the
combined action of Cbx3 and the H3K9 methyltransferases
Ehmt1, Ehmt2, and Setdb1. Intriguingly, Cbx3, Ehmt1, and
Ehmt2 were all detected as part of Nanog protein complexes
in mouse ESCs (Gagliardi et al., 2013). This overlap suggests
that recruitment of H3K9 methyltransferases may constitute a
constraint on the activity of Nanog, similar to recruitment of the
transcriptional corepressor Zfp281, which mediates Nanog au-
torepression (Fidalgo et al., 2012).
Demethylation of pluripotency-associated promoter regions
represents a critical epigenetic event during somatic cell reprog-
ramming (Mikkelsen et al., 2008) and is thought to take place af-
ter transcriptional and histone modification changes (Polo et al.,
2012) (Figure 1A). While DNA demethylation can occur through a
passive mechanism involving the gradual loss of methylation by
the maintenance DNA methyltransferase Dnmt1 in the course of
cell division, active mechanisms for demethylation have been
implicated in the reprogramming process. For example, activa-
tion-induced cytidine deaminase (AID) mediates deamination
of 5mC to thymine, which is subject to DNA repair, resulting in
cytosine exchange and demethylation. Knockdown of AID was
used to show that the enzyme is required for initiation of nuclear
reprogramming by cell fusion in the absence of DNA replication
(Bhutani et al., 2010). However, other studies reported a require-
ment for DNA replication during fusion-mediated reprogramming
(Foshay et al., 2012; Tsubouchi et al., 2013), suggesting that pas-
sive mechanisms are involved instead. In addition, it has been
shown that AID deficiency destabilizes late but not early events
during iPSC formation (Kumar et al., 2013) or is even fully
dispensable (Shimamoto et al., 2014). Thus, the role of AID in
epigenetic reprogramming remains unresolved.
Another possible mechanism for active DNA demethylation
implicated during induced pluripotency is the conversion of
5mC into 5-hydroxymethylcytosine (5hmC), which may subse-
quently be converted into cytosine through mechanisms
involving the base excision repair pathway. The ten-eleven trans-
location (Tet) family methylcytosine hydroxylases Tet1 and Tet2
were shown to form a physical interaction with Nanog, and coex-
pression of Nanog with either Tet1 or Tet2 enhanced the effi-
ciency of reprogramming (Costa et al., 2013). Nanog-dependentCell Stem Cell 14, June 5, 2014 ª2014 Elsevier Inc. 729
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Oct4, promoted conversion of 5mC into 5hmC. Further support
for the role of Tet enzymes comes from reports that Tet1 can
replace Oct4 during reprogramming (Gao et al., 2013), while ge-
netic ablation of Tet1, Tet2, and Tet3 blocked reprogramming in
fibroblasts by interfering with the demethylation and reactivation
of miRNAs required for MET (Hu et al., 2014). Pei and colleagues
demonstrated that, in the presence of vitamin C, Tet1 actually
behaves as a barrier to reprogramming by inhibiting MET
(Chen et al., 2013a). On the other hand, Tet2 had a constitutively
positive effect at all levels of vitamin C. Tet2 was also implicated
in the establishment of a permissive chromatin signature at the
Nanog and Esrrb loci during the early stage of reprogramming
(Doege et al., 2012). In this context Tet2 cooperated with
poly(ADP-ribose) polymerase 1 (Parp1), a nuclear protein
involved in DNA damage repair, to control the levels of 5mC
and 5hmC. Another family of DNA repair proteins involved in re-
programming aremembers of the XPC nucleotide excision repair
complex, which is recruited by Oct4 and Sox2 to the Nanog and
Oct4 promoters (Fong et al., 2011).
The above examples illustrate how various modulators of
induced pluripotency are recruited to specific DNA targets by
transcriptional ‘‘drivers’’ of reprogramming. However, some
epigenetic regulators have globally adverse or beneficial conse-
quences for the pluripotent state. An example of an epigenetic
modifier with a globally adverse role is the histone variant mac-
roH2A, whose removal enhanced the efficiency of reprogram-
ming (Gaspar-Maia et al., 2013; Pasque et al., 2012). MacroH2A
is depleted in pluripotent cells, and its deposition is thought to
repress pluripotency factors in differentiated cells. MacroH2A
isoforms were particularly enriched at target genes of Utx, which
are reactivated early during reprogramming (Gaspar-Maia et al.,
2013). Conversely, an epigenetic modification implicated in pro-
moting the final stages of induced pluripotency is citrullination of
arginine residues mediated by the peptidylarginine deiminase
Padi4 (Christophorou et al., 2014). This enzyme was upregulated
during reprogramming and disrupted the binding of histone H1 to
nucleosomal DNA, contributing to chromatin decondensation in
pluripotent cells.
Finally, even manipulation of the general transcriptional and
translational apparatus can influence the kinetics of reprogram-
ming. Timmers and colleagues reported that high levels of TFIID,
which is central to transcription initiation by RNA polymerase II,
are essential for reprogramming and the self-renewal of pluripo-
tent cells (Pijnappel et al., 2013). A plausible explanation for the
selective TFIID dependency observed in the pluripotent state is
that promoter sequences of core pluripotency genes have
reduced affinity for TFIID. Similarly, depletion of eukaryotic
translation initiation factor 4E (eIF4E) binding proteins (4E-
BPs), which are translational repressors, reduced the efficiency
of somatic cell reprogramming in part through enhanced transla-
tion of p21 mRNA (Tahmasebi et al., 2014). As p53 inhibits re-
programming by stimulating p21 transcription, the authors
reasoned that loss of p53 would rescue the reprogramming
deficit caused by the loss of 4E-BPs. In fact, depletion of 4E-
BPs in p53/ fibroblasts resulted in increased reprogramming
compared to wild-type fibroblasts. This effect was explained
by reduced transcription of p21 and higher levels of Sox2 and
c-Myc, whose translation is eIF4E dependent. Accordingly,730 Cell Stem Cell 14, June 5, 2014 ª2014 Elsevier Inc.expression of exogenous Oct4 alone was sufficient to induce
pluripotency in p53/;4E-BP1/2/ fibroblasts, providing yet
another variation on Yamanaka’s reprogramming cocktail
(Figure 3A).
Concluding Remarks
Recent developments in epigenetic reprogramming require us
to reconsider long-held assumptions about the process of
induced pluripotency. iPSC generation with the Yamanaka fac-
tors was thought to be inherently a stochastic process, but
this view has been challenged by observations of deterministic
reprogramming using additional genetic manipulation or
different populations of donor cells. The question of stochastic-
ity is symptomatic of a broader challenge for research into the
molecular mechanisms of epigenetic reprogramming. As novel
methods to induce pluripotency continue to be discovered,
past assumptions about the parameters affecting reprogram-
ming must be re-evaluated. Only a comparative approach can
distinguish essential regulators and mechanisms from the idio-
syncrasies of individual reprogramming methods. For this
reason it will be especially illuminating to compare the sequence
of events during chemical reprogramming or nuclear transfer
with the roadmaps of transcription factor-induced reprogram-
ming described above.
A second major aim of future experimental work will be to
define crosstalk among the numerous molecular agents impli-
cated in the reprogramming process. The growing repertoire of
transcription factors capable of generating iPSC has repudiated
the concept, once prevalent, of a pluripotent state governed by a
triad of master transcription factors. Further complexity arises
from long-range chromosomal interactions that connect several
pluripotency-associated loci (Apostolou and Hochedlinger,
2013). In addition, high-throughput chemical screens and
proteomic studies have identified a spectrum of chromatin re-
modelers, histone modifiers, DNA repair proteins, and 5mC
hydroxylases that alter the kinetics of reprogramming. Many of
these enzymes were implicated in the transcriptional regulation
of core pluripotency genes. However, regulatory interactions be-
tween the upstream regulators themselves remain incompletely
understood. The litmus test for any systems-level model of
epigenetic reprogrammingwill be to establish a functional hierar-
chy among these factors.
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